Antibody‐Targeted Photodynamic Therapy

摘要: Photodynamic therapy (PDT) is a clinically approved treatment modality for cancer and superficial lesions. It harnesses the photochemical reaction between lightsensitizing drug oxygen to generate cytotoxic reactive species which destroy cells. Although with many benefits, its complexity, lack of potency side effects have led poor general usage. However, research area very active an increasing understanding PDT-related cell biology, photophysics significant progress in molecular targeting disease leading next generation PDT. Monoclonal antibody successful wave monoclonal therapies-antibody-drug conjugates (ADCs) could also sweep antibodytargeted PDT success. Antibody-targeted promises increase specificity improve pharmacokinetics thus delivering better drugs whilst retaining other benefits. Whole first photosensitisers displayed problems aggregation, loss immuno-reactivity. these early photo-immunoconjugates still showed improved selectivity potency. Improved photosensitiser chemistry variety conjugation strategies retained function. More recently, recombinant fragments been used form good loading, more favourable pharmacokinetics, enhanced target selectivity.